IVIG Treatment Insurance Denied? How to Appeal

Intravenous immunoglobulin (IVIG) is a life-sustaining therapy for patients with primary immunodeficiencies, certain autoimmune neurological conditions, and a range of other serious immune-mediated diseases. For many patients, IVIG is not optional — it is the difference between health and recurrent, life-threatening infections or progressive neurological disability. Yet insurance denials for IVIG are surprisingly common, driven by high cost, complex documentation requirements, and insurer clinical criteria that sometimes diverge from accepted medical standards. If your insurer has denied IVIG coverage, a well-constructed appeal has a strong chance of success.

Why Insurers Deny IVIG Treatment

Diagnosis-based coverage restrictions are the most common denial mechanism. Insurers approve IVIG for a limited list of "covered indications" and deny all other uses — even when the clinical evidence strongly supports the treatment and the prescribing physician is a board-certified immunologist or neurologist. FDA-approved indications for IVIG include primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). Off-label uses — including secondary immunodeficiencies, autoimmune encephalitis, inflammatory myopathies, and others — may have strong clinical guideline support despite being outside the FDA's labeled indications.

Documentation gap denials occur even for covered indications when clinical records do not clearly satisfy every criterion in the insurer's coverage policy. For primary immunodeficiency (ICD-10: D83.9 for common variable immunodeficiency, D80.0 for X-linked agammaglobulinemia), policies typically require documented baseline immunoglobulin levels (IgG below 400-600 mg/dL), recurrent serious infections despite antibiotic treatment, and immunology specialist evaluation. Missing any element triggers a denial.

Site-of-care disputes arise when the insurer approves IVIG but requires infusion in a lower-cost setting (typically a physician's office or home infusion) than the patient's treating team recommends (typically an infusion center or hospital outpatient setting). These disputes often have clinical implications, particularly for patients with complex immune conditions who require monitoring during infusion.

Step therapy or alternative therapy requirements apply when the insurer requires the patient to try subcutaneous immunoglobulin (SCIG) before approving IVIG, or to trial other immunosuppressive agents before approving IVIG for neurological conditions such as CIDP (ICD-10: G61.81) or MMN (ICD-10: G61.82).

Continuation of therapy denials occur after an initial approval when the insurer declines to reauthorize ongoing IVIG, claiming insufficient evidence of benefit. For primary immunodeficiency patients, IVIG is a lifetime maintenance therapy — discontinuation results in recurrence of serious infections.

How to Appeal an IVIG Denial

Step 1: Obtain the Full Denial and Insurer's Clinical Policy

Request the complete denial letter and your insurer's written IVIG coverage policy or clinical criteria document. This document specifies which diagnoses are covered, what documentation is required, and what clinical thresholds must be met. Comparing your medical records against this criteria document will reveal exactly what documentation gaps or criteria disputes the appeal must address.

Step 2: Document the Diagnosis with Precise ICD-10 Coding and Laboratory Evidence

Work with your treating immunologist or neurologist to ensure your clinical records clearly establish the diagnosis and satisfy each element of the insurer's coverage criteria. For primary immunodeficiency: document baseline IgG levels (pre-treatment), IgA and IgM levels, lymphocyte subsets, and the history of recurrent serious infections with dates, organisms, and treatments. For CIDP: document nerve conduction study results confirming the demyelinating pattern, clinical examination findings, and disability assessment. For ITP: document platelet counts and bleeding history. Accurate ICD-10 coding (D83.9, D80.0, G61.81, G61.82, D69.3 for ITP) must be present throughout the medical record.

Step 3: Obtain a Comprehensive Letter of Medical Necessity from Your Specialist

Your treating immunologist or neurologist — a board-certified specialist, not a primary care provider — must write a detailed medical necessity letter that: (1) establishes the diagnosis with ICD-10 code and supporting laboratory or electrophysiologic evidence, (2) documents prior treatment history and outcomes, (3) explains why IVIG is medically necessary and the clinical consequences of denial, and (4) cites the applicable clinical guidelines. For primary immunodeficiency, cite the International Patient Organisation for Primary Immunodeficiencies (IPOPI) and the American Academy of Allergy, Asthma & Immunology (AAAAI) guidelines. For CIDP, cite the European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society (PNS) joint guidelines and the AANeurology practice guidelines.

Step 4: Address Off-Label Use Arguments with Evidence-Based Literature

If your denial cites off-label use, your appeal must directly address this. Present peer-reviewed publications — including systematic reviews and clinical practice guidelines — that establish the clinical basis for IVIG use in your specific condition. The American Academy of Neurology (AAN), the American College of Rheumatology (ACR), and the AAAAI all publish evidence-based guidelines that support IVIG use in conditions beyond the narrow FDA label.

Step 5: Request Peer-to-Peer Review Between Your Specialist and the Insurer

Before or alongside filing a formal written appeal, ask your treating specialist to request a peer-to-peer review with the insurer's medical reviewer. Conversations between a board-certified immunologist or neurologist and the insurer's reviewer frequently resolve denials that persist through written appeals. Request that the insurer's reviewer have relevant specialty expertise.

Step 6: Pursue External Independent Review

If the internal appeal is denied, request independent external review through your state insurance commissioner. External reviewers are specialist physicians who apply objective clinical standards — and for IVIG denials with strong clinical documentation, external review has a high overturn rate.

What to Include in Your Appeal

• Full denial letter with the specific coverage criteria applied and denial reason
• Laboratory results: baseline and current IgG, IgA, IgM levels, lymphocyte subset panels (for immunodeficiency), or nerve conduction study results (for CIDP/MMN)
• Medical records documenting infection history or neurological disability progression
• ICD-10 diagnosis codes clearly documented in clinical records (D83.9, D80.0, G61.81, G61.82, D69.3 as applicable)
• Treating specialist's medical necessity letter citing AAAAI, AAN, EFNS/PNS, or ACR guidelines
• Peer-reviewed clinical guidelines and literature supporting the indication, particularly for off-label uses

Fight Back With ClaimBack

IVIG denials often come down to documentation gaps or overly narrow insurer criteria that contradict the clinical guidelines your immunologist or neurologist follows — and a well-documented appeal, supported by your specialist's letter and guideline citations, frequently succeeds in overturning the denial. ClaimBack generates a professional appeal letter in 3 minutes, tailored to the specific diagnosis and IVIG indication in your case.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal